A randomized phase II study of paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus and ixabepilone/carboplatin/bevacizumab as initial therapy for measurable stage III or IVA, stage IVB or recurrent endometrial cancer, GOG-86P.-Reference-Cited by-同舟云学术

A randomized phase II study of paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus and ixabepilone/carboplatin/bevacizumab as initial therapy for measurable stage III or IVA, stage IVB or recurrent endometrial cancer, GOG-86P.

Published:2015-05-20 Issue:15_suppl Volume:33 Page:5500-5500
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Aghajanian Carol¹,Filiaci Virginia L.²,Dizon Don S.³,Carlson Jay⁴,Powell Matthew A.⁵,Secord Angeles Alvarez⁶,Tewari Krishnansu Sujata⁷,Bender David⁸,O'Malley David M.⁹,Stuckey Ashley¹⁰,Rotmensch Jacob¹¹,Levine Douglas A.¹²,Lankes Heather A.¹³,Moore Kathleen N.¹⁴

Affiliation:

1. Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY

2. NRG Oncology and GOG Foundation Inc SDMC, Buffalo, NY

3. Massachusetts General Hospital, Boston, MA

4. Cancer Research for the Ozarks, Springfield, MO

5. Washington University School of Medicine in St. Louis, St. Louis, MO

6. Division of Gynecologic Oncology, Duke Cancer Institute, Duke University Medical Center, Durham, NC

7. UC Irvine Medical Center, Orange, CA

8. University of Iowa, Iowa City, IA

9. The Ohio State University College of Medicine, Columbus, OH

10. Women and Infants Hospital, Providence, RI

11. University Gyn Onc Assoc, Chicago, IL